This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
What’s the impact of SARS-CoV-2 on community transmission and the blood supply?
Supporting research to understand blood safety and SARS-CoV-2 pathogenesis with the RESPONSE program
Challenge
SARS-CoV-2 social distancing protocols have had a negative impact on the U.S. blood supply, creating the imperative to assess whether individuals with potential SARS-CoV-2 exposure or asymptomatic infection need to be deferred from blood donation.
The National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID) jointly funded the REDS Epidemiology, Surveillance, and Preparedness of the Novel SARS-CoV-2 Epidemic program (RESPONSE) through the Recipient Epidemiology and Donor Evaluation Study IV–Pediatric (REDS-IV-P) program. RESPONSE addresses key issues related to blood safety and furthers our understanding of SARS-CoV-2 natural history and pathogenesis.
Solution
To address these objectives, the RESPONSE program is:
- Conducting serosurveys to study antibody reactivity;
- Enrolling SARS-CoV-2-positive subjects in a longitudinal cohort study to answer fundamental questions on the evolution of viremia and early immune response; and
- Establishing a shareable biorepository for future research.
Westat, as the Data Coordinating Center for the REDS-IV-P program, is using its suite of tools to support all aspects of the RESPONSE protocols, including: subject enrollment and consent; online surveys; data entry forms; biospecimen management; and monitoring, reporting, and analyzing study data. These tools provide flexibility, responsiveness, and capacity with respect to the study protocols, while also ensuring high-quality data for analysis. Our statisticians are using advanced statistical techniques to extrapolate seroprevalence from sampled blood donors to the general population.
Results
Serosurveys conducted in 6 U.S. regions showed increased seroreactivity between March and August 2020. Analysis published in the journal Transfusion also showed that SARS-CoV-2 does not appear to pose a threat to the nation’s blood supply. See the National Institutes of Health news release: U.S. blood donations are safe under current COVID-19 screening guidelines.
Westat and other partners are now using the same statistical approach developed for RESPONSE to support the Centers for Disease Control and Prevention (CDC) in conducting a national serosurvey in 60+ U.S. regions. Learn more about our work conducting the Multistate Assessment of SARS-CoV-2 Seroprevalence in Blood Donors, the largest nationwide COVID-19 seroprevalence survey.
Data collected from the ongoing RESPONSE longitudinal cohort will lead to a better understanding of SARS-CoV-2 immune response and the dynamics of antibody persistence.
Focus Areas
Clinical Research Clinical Trials Coordinating Centers Multisite Epidemiology StudiesCapabilities
Advanced Technologies Biostatistics and Epidemiology Data Collection Data Collection Modes Data ManagementSenior Expert Contact
Sunitha Mathew
Vice President & Practice Director, Clinical Research
-
Perspective
Teacher Apprenticeships Strengthen the WorkforceJuly 2024
Many state education agencies (SEAs) are addressing teacher shortages by creating and expanding alternative paths to the teaching profession. One fast-growing option is teacher apprenticeships,…
-
Expert Interview
Passport to Careers: Aiding Foster and Homeless Young AdultsJuly 2024
The Passport to Careers program in Washington State supports former foster youth and homeless youth unaccompanied by a parent or guardian in achieving their college…
-
Perspective
Highlights of Westat at AAPOR 2024May 2024
We’ve returned from the 79th Annual American Association for Public Opinion Research (AAPOR) Conference, held May 15-17 in Atlanta, where we caught up with colleagues…